• James T England, Alym Abdulla, Catherine M Biggs, Lee Agnes Y Y AYY Division of Hematology, University of British Columbia, Canada., Kevin A Hay, Ryan L Hoiland, Cheryl L Wellington, Mypinder Sekhon, Shahin Jamal, Kamran Shojania, and Luke Y C Chen.
• Division of Hematology, University of British Columbia, Canada.
• Blood Rev. 2021 Jan 1; 45: 100707.

AbstractA subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a "Cytokine Storm Syndrome" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS.© 2020 Elsevier Ltd. All rights reserved.

53 keywords...

hide…